FDA
-
-
-
-
-
-
-
Ohr Pharmaceutical Reports Fiscal Year 2017 Financial Results
-
-
-
-
-
-
-
Ohr Pharmaceutical (OHRP) Amends Trial of Squalamine in Wet-AMD to Enable Efficacy Analyses by End of 2017 or Early 2018
-
-
-
-
-
-
-
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
-
-
323,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

